B7-H3 ADCs in small cell lung cancer

8 selected Phase 3 trial records across 4 assets: ifinatamab deruxtecan, risvutatug rezetecan, YL201, and MHB088C / QLC5508.

Hover for trial details. Click or tap a dot to keep them open.

Trial ID	Asset	Phase	Recorded status	Trial
NCT06203210	ifinatamab deruxtecan	3	Active	Ifinatamab Deruxtecan (I-DXd) vs Treatment of Physician's Choice in Relapsed Small Cell Lung Cancer
NCT06498479	risvutatug rezetecan	3	Active	HS-20093 vs Topotecan in Relapsed Small Cell Lung Cancer
NCT06526624	risvutatug rezetecan	3	Active	HS-20093 vs Active Surveillance in LS-SCLC
NCT06612151	YL201	3	Active	YL201 vs Topotecan in Relapsed Small Cell Lung Cancer
NCT06954246	MHB088C / QLC5508	3	Active	MHB088C vs TPC in Relapsed SCLC
NCT07099898	risvutatug rezetecan	3	Active	Risvutatug rezetecan vs Topotecan in Relapsed SCLC
NCT07739758	YL201	3	Active	YL201 + Serplulimab vs Carboplatin + Etoposide + Serplulimab in 1L ES-SCLC
NCT07802821	MHB088C / QLC5508	3	Active	QLC5508 + QL2107 vs Tislelizumab + Chemotherapy in Extensive-stage Small Cell Lung Cancer

Trial counts are grouped by asset. Statuses reflect the database classification at capture.

Which B7-H3 ADCs have Phase 3 trials in small cell lung cancer?